557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial
Patrizia Froesch(Institute of Oncology Research), Martin Früh(University of Bern), Q. Li(Swiss Group For Clinical Cancer Research), Ilaria Colombo(Ente Ospedaliero Cantonale), Michael Mark(Kantonsspital Graubünden), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Helen Thut(University Hospital of Basel), Yannis Metaxas(Kantonsspital Graubünden), Gilles Godar(Swiss Group For Clinical Cancer Research), Sabine Schmid(University of Bern), Sacha I. Rothschild(University Hospital of Basel), C. Sessa(Vita-Salute San Raffaele University), Corinne Rusterholz(Swiss Group For Clinical Cancer Research)
Cited by 1
Related Papers
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2011|580
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|288